RESUMO
Effective cardiovascular prevention requires taking advantage of all opportunities for patient contact with the Health Services in order to detect risk factors (CVRF) and global cardiovascular risk stratification (CVR). This particularly involves the Primary Care (PC) services, which must be coordinated with the Hospital Care (HC) in order to make all health resources available to the population. In addition, it is necessary to take into account the contribution of Occupational Health and Pharmacy services. There are hopeful signs as regards the possibility of overcoming the barriers that limit the necessary exchange of information between PC and HC professionals, as a basis for adequate coordination between both levels of care. This includes the implementation of referral and discharge algorithms (in this review this means those related to dyslipidaemias) accepted by professionals at both levels, and currently facilitated by the availability of new corporate tools (mobile, email, virtual consultations). The challenge lies in seizing the opportunity they offer to make their implementation effective.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Atenção à Saúde/organização & administração , Dislipidemias/terapia , Algoritmos , Doenças Cardiovasculares/etiologia , Dislipidemias/complicações , Fatores de Risco de Doenças Cardíacas , Hospitais , Humanos , Alta do Paciente , Atenção Primária à Saúde/organização & administração , Encaminhamento e Consulta/organização & administraçãoRESUMO
Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine.
Assuntos
Diabetes Mellitus Tipo 2 , Estado Pré-Diabético , Diabetes Mellitus Tipo 2/dietoterapia , Humanos , Obesidade/dietoterapia , Sobrepeso/dietoterapia , Estado Pré-Diabético/dietoterapiaRESUMO
Adequate lifestyle changes significantly reduce the cardiovascular risk factors associated with prediabetes and type 2 diabetes mellitus. Therefore, healthy eating habits, regular physical activity, abstaining from using tobacco, and good sleep hygiene are recommended for managing these conditions. There is solid evidence that diets that are plant-based; low in saturated fatty acids, cholesterol, and sodium; and high in fiber, potassium, and unsaturated fatty acids are beneficial and reduce the expression of cardiovascular risk factors in these subjects. In view of the foregoing, the Mediterranean diet, the DASH diet, a low-carbohydrate diet, and a vegan-vegetarian diet are of note. Additionally, the relationship between nutrition and these metabolic pathologies is fundamental in targeting efforts to prevent weight gain, reducing excess weight in the case of individuals with overweight or obesity, and personalizing treatment to promote patient empowerment. This document is the executive summary of an updated review that includes the main recommendations for improving dietary nutritional quality in people with prediabetes or type 2 diabetes mellitus. The full review is available on the webpages of the Spanish Society of Arteriosclerosis, the Spanish Diabetes Society, and the Spanish Society of Internal Medicine.
RESUMO
A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Laboratorios Esteve, S.A.
Assuntos
Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/complicações , Lipídeos/sangue , Pressão Sanguínea , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/terapia , Diabetes Mellitus Tipo 2/terapia , Humanos , Hipoglicemiantes/uso terapêutico , Inibidores da Agregação Plaquetária/uso terapêutico , Fatores de RiscoRESUMO
A consumption of 2 grams per day of plant sterols produces an inhibition of intestinal absorption of cholesterol and reduces the plasma concentration of c-LDL (cholesterol associated with low-density lipoprotein) by around 10%, which has determined its incorporation into different food products like margarines or dairy. The plant sterols develop their action in the intestine, where they reduce the absorption of cholesterol increasing their elimination fecal. In clinical practice, the use of functional foods with plant sterols at the recommended doses can be considered as a complement to lifestyle modifications, in individuals with hypercholesterolemia and low cardiovascular risk but who do not require hypocholesterolemic pharmacological treatment, and also in those patients receiving pharmacological treatment with lipid-lowering drugs and who do not get the therapeutic goals of c-LDL. The hypocholesterolemic effect of plant sterols is additive to that achieved with changes in lifestyle and/or other lipid-lowering agents. Coadministration with statins generates a hypocholesterolemic effect usually greater than that obtained when the statin dose is doubled.
Un consumo de 2 gramos diarios de esteroles vegetales produce una inhibición de la absorción intestinal de colesterol y reduce la concentración plasmática de c-LDL (colesterol asociado a lipoproteínas de baja densidad) alrededor de un 10%, lo que ha determinado su incorporación a diferentes productos alimenticios como margarinas o lácteos. Los esteroles vegetales desarrollan su acción en el intestino, donde dificultan la absorción del colesterol aumentando su eliminación a través de las heces.En la práctica clínica, la utilización de alimentos funcionales con esteroles vegetales a las dosis recomendadas se puede considerar como complemento de las modificaciones del estilo de vida, en individuos con hipercolesterolemia y riesgo cardiovascular global bajo, pero que no precisen tratamiento farmacológico hipocolesterolemiante, y también en aquellos pacientes que reciben tratamiento farmacológico con hipolipemiantes y que no alcanzan los objetivos terapéuticos de c-LDL. El efecto hipocolesterolemiante de los esteroles vegetales es aditivo al alcanzado con los cambios del estilo de vida y/o con otros hipolipemiantes. La coadministración con estatinas genera un efecto hipocolesterolemiante habitualmente superior al obtenido cuando se dobla la dosis de estatina.
Assuntos
Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Fitosteróis/uso terapêutico , Preparações de Plantas/uso terapêutico , LDL-Colesterol/sangue , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêuticoRESUMO
INTRODUCTION AND OBJECTIVES: Despite the recognized clinical benefit of statins on cardiovascular prevention, providing correct management of hypercholesterolaemia, possible adverse effects of their use cannot be disregarded. Previously published data shows that there is a risk of developing diabetes mellitus or experiencing changes in glucose metabolism in statin-treated patients. The possible determining factors are the drug characteristics (potency, dose), patient characteristics (kidney function, age, cardiovascular risk and polypharmacy because of multiple disorders) and the pre-diabetic state. METHODS: In order to ascertain the opinion of the experts (primary care physicians and other specialists with experience in the management of this type of patient) we conducted a Delphi study to evaluate the consensus rate on diverse aspects related to the diabetogenicity of different statins, and the factors that influence their choice. RESULTS: Consensus was highly significant concerning aspects such as the varying diabetogenicity profiles of different statins, as some of them do not significantly worsen glucose metabolism. There was an almost unanimous consensus that pitavastatin is the safest statin in this regard. CONCLUSIONS: Factors to consider in the choice of a statin regarding its diabetogenicity are the dose and patient-related factors: age, cardiovascular risk, diabetes risk and baseline metabolic parameters (which must be monitored during the treatment), as well as kidney function.
Assuntos
Diabetes Mellitus Tipo 2/induzido quimicamente , Glucose/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Estado Pré-Diabético/induzido quimicamente , Consenso , Técnica Delphi , Diabetes Mellitus Tipo 2/sangue , Humanos , Hipercolesterolemia/tratamento farmacológico , Médicos de Atenção Primária , Inquéritos e QuestionáriosRESUMO
This paper describes what are plant sterols, the chemical structure to understand their mechanism of cholesterol-lowering action, and indications and contraindications in clinical practice.
Assuntos
Anticolesterolemiantes/uso terapêutico , Fitosteróis/uso terapêutico , Anticolesterolemiantes/química , Anticolesterolemiantes/farmacologia , Colesterol/sangue , Humanos , Fitosteróis/química , Fitosteróis/farmacologiaRESUMO
BACKGROUND AND OBJECTIVES: This post hoc study analysed the perception of the relevance of chronic kidney disease (CKD) in dyslipidaemia screening and the choice of statin among primary care physicians (PCPs) and other specialists through a Delphi questionnaire. METHODS: The questionnaire included 4blocks of questions concerning dyslipidaemic patients with impaired carbohydrate metabolism. This study presents the results of the impact of CKD on screening and the choice of statin. RESULTS: Of the 497 experts included, 58% were PCPs and 42% were specialists (35, 7% were nephrologists). There was consensus by both PCPs and specialists, with no difference between PCPs and specialists, that CKD patients should undergo a dyslipidaemia screening and that the screening should be part of routine clinical practice. However, there was no consensus in considering the estimated glomerular filtration rate (eGFR) (although there was consensus among PCPs and nephrologists), or considering albuminuria when selecting a statin, or in determining albuminuria during follow-up after having initiated treatment with statins (although there was consensus among the nephrologists). CONCLUSIONS: The consensus to analyse the lipid profile in CKD patients suggests acknowledgment of the high cardiovascular risk of this condition. However, the lack of consensus in considering renal function or albuminuria, both when selecting a statin and during follow-up, suggests a limited knowledge of the differences between statins in relation to CKD. Thus, it would be advisable to develop a guideline/consensus document on the use of statins in CKD.
Assuntos
Dislipidemias/diagnóstico , Dislipidemias/terapia , Insuficiência Renal Crônica/complicações , Albuminúria , Doenças Cardiovasculares , Consenso , Técnica Delphi , Taxa de Filtração Glomerular , Humanos , Lipídeos/sangue , Fatores de Risco , Inquéritos e QuestionáriosRESUMO
INTRODUCTION: Treatment of atherogenic dyslipidemia (AD) in type 2 diabetes (DM2) should focus on the global control of dyslipidemia. The aim of this study was to determine how hospital (MSs) and primary care specialist (GPs) from Spain manage AD in DM2 during their daily practice. METHODS: An observational, cross-sectional, multicentric study was conducted. Information about daily practice was obtained from 497 MSs and 872 GPs across Spain. RESULTS: 66% of MSs and 30.5% of GPs considered DM2 patients to be high-risk. Most consider the c-LDL targets based on European guidelines. The statins most widely used are atorvastatin and simvastatin. However both MSs and GPs considered rosuvastatin to be the most appropriate statin for these patients. 82% of MSs and 68% of GPs considered that >50% of their patients achieved the c-LDL target. The main reasons of not achieving this target were lack of treatment adherence and pressure from the administration. Seventy four percent of MSs reported that there are no common clinical protocols with GPs. CONCLUSIONS: The differences in the perception of the real cardiovascular risk of the patient, low use of more appropriate statins, lack of adherence and poor perception of real c-LDL control may contribute to the failure in achieving lipid targets in DM2.
Assuntos
Aterosclerose/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Dislipidemias/tratamento farmacológico , Hipolipemiantes/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Estudos Transversais , Pesquisas sobre Atenção à Saúde , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipolipemiantes/administração & dosagem , Lipídeos/sangue , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/estatística & dados numéricos , Fatores de Risco , EspanhaRESUMO
Un consumo de 2 gramos diarios de esteroles vegetales produce una inhibición de la absorción intestinal de colesterol y reduce la concentración plasmática de c-LDL (colesterol asociado a lipoproteínas de baja densidad) alrededor de un 10%, lo que ha determinado su incorporación a diferentes productos alimenticios como margarinas o lácteos. Los esteroles vegetales desarrollan su acción en el intestino, donde dificultan la absorción del colesterol aumentando su eliminación a través de las heces. En la práctica clínica, la utilización de alimentos funcionales con esteroles vegetales a las dosis recomendadas se puede considerar como complemento de las modificaciones del estilo de vida, en individuos con hipercolesterolemia y riesgo cardiovascular global bajo, pero que no precisen tratamiento farmacológico hipocolesterolemiante, y también en aquellos pacientes que reciben tratamiento farmacológico con hipolipemiantes y que no alcanzan los objetivos terapéuticos de c-LDL. El efecto hipocolesterolemiante de los esteroles vegetales es aditivo al alcanzado con los cambios del estilo de vida y/o con otros hipolipemiantes. La coadministración con estatinas genera un efecto hipocolesterolemiante habitualmente superior al obtenido cuando se dobla la dosis de estatina (AU)
A consumption of 2 grams per day of plant sterols produces an inhibition of intestinal absorption of cholesterol and reduces the plasma concentration of c-LDL (cholesterol associated with low-density lipoprotein) by around 10%, which has determined its incorporation into different food products like margarines or dairy. The plant sterols develop their action in the intestine, where they reduce the absorption of cholesterol increasing their elimination fecal. In clinical practice, the use of functional foods with plant sterols at the recommended doses can be considered as a complement to lifestyle modifications, in individuals with hypercholesterolemia and low cardiovascular risk but who do not require hypocholesterolemic pharmacological treatment, and also in those patients receiving pharmacological treatment with lipid lowering drugs and who do not get the therapeutic goals of c-LDL. The hypocholesterolemic effect of plant sterols is additive to that achieved with changes in lifestyle and/or other lipid-lowering agents. Coadministration with statins generates a hypocholesterolemic effect usually greater than that obtained when the statin dose is doubled (AU)
Assuntos
Humanos , Esteróis/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Alimento Funcional , Fitosteróis/uso terapêutico , Estilo de Vida , Colesterol/química , Resultado do Tratamento , LDL-ColesterolRESUMO
Antecedentes y objetivos: Este estudio post hoc analizó la percepción de la importancia de la enfermedad renal crónica (ERC) en el cribado de la dislipidemia y en la elección del tratamiento con estatinas entre médicos de Atención Primaria (MAP) y otras especialidades mediante cuestionario Delphi. Métodos: El cuestionario incluyó 4 bloques de preguntas alrededor del paciente dislipémico con alteración del metabolismo hidrocarbonado. Aquí se presentan los resultados relacionados con la consideración de la ERC en el cribado y la elección de la estatina. Resultados: De los 497 expertos incluidos, el 58% eran MAP y el 42%, especialistas (35, el 7%, nefrólogos). Hubo consenso en realizar un cribado de la dislipidemia en los pacientes con ERC, sin diferencias entre MAP y especialistas; y también en realizar el cribado en la práctica clínica habitual. Sin embargo, no se alcanzó el consenso en considerar el filtrado glomerular estimado (aunque sí entre MAP y nefrólogos) o la albuminuria en la elección de la estatina, ni en su determinación durante el seguimiento después de instaurar un tratamiento con estatinas (aunque hubo consenso entre nefrólogos). Conclusiones: El consenso en analizar el perfil lipídico en los pacientes con ERC indica el reconocimiento del alto riesgo cardiovascular de esta enfermedad. La ausencia de acuerdo en considerar la función renal o la albuminuria, tanto en la elección de la estatina como durante el seguimiento, indica un conocimiento limitado de las diferencias entre estatinas en relación con la ERC, por lo que sería deseable disponer de una guía/documento de consenso sobre uso de estatinas en la ERC (AU)
Background and objectives: This post hoc study analysed the perception of the relevance of chronic kidney disease (CKD) in dyslipidaemia screening and the choice of statin among primary care physicians (PCPs) and other specialists through a Delphi questionnaire. Methods: The questionnaire included 4 blocks of questions concerning dyslipidaemic patients with impaired carbohydrate metabolism. This study presents the results of the impact of CKD on screening and the choice of statin. Results: Of the 497 experts included, 58% were PCPs and 42% were specialists (35, 7% were nephrologists). There was consensus by both PCPs and specialists, with no difference between PCPs and specialists, that CKD patients should undergo a dyslipidaemia screening and that the screening should be part of routine clinical practice. However, there was no consensus in considering the estimated glomerular filtration rate (eGFR) (although there was consensus among PCPs and nephrologists), or considering albuminuria when selecting a statin, or in determining albuminuria during follow-up after having initiated treatment with statins (although there was consensus among the nephrologists). Conclusions: The consensus to analyse the lipid profile in CKD patients suggests acknowledgment of the high cardiovascular risk of this condition. However, the lack of consensus in considering renal function or albuminuria, both when selecting a statin and during follow-up, suggests a limited knowledge of the differences between statins in relation to CKD. Thus, it would be advisable to develop a guideline/consensus document on the use of statins in CKD (AU)
Assuntos
Humanos , Dislipidemias/tratamento farmacológico , Insuficiência Renal Crônica/complicações , Programas de Rastreamento/métodos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Atenção Primária à Saúde , Dislipidemias/diagnósticoRESUMO
En este trabajo se describe qué son los esteroles vegetales, la estructura química de los mismos para entender su mecanismo de acción hipocolesterolemiante, así como sus indicaciones y sus contraindicaciones en la práctica clínica
This paper describes what are plant sterols, the chemical structure to understand their mechanism of cholesterol-lowering action, and indications and contraindications in clinical practice
Assuntos
Humanos , Fitosteróis/farmacocinética , Anticolesterolemiantes/farmacocinética , Doenças Cardiovasculares/prevenção & controle , Hipercolesterolemia/tratamento farmacológico , Fatores de Risco , Padrões de Prática MédicaRESUMO
Introducción: El tratamiento de la dislipidemia aterogénica en el paciente con diabetes tipo 2 (DM2) debe ir encaminado al control global del perfil lipídico. El objetivo de este estudio fue analizar cómo se realiza el control de la dislipidemia aterogénica en la DM2 por médicos especialistas hospitalarios (ME) y de atención primaria (MAP). Métodos: Estudio ecológico, descriptivo, transversal y multicéntrico que recogió la información de 497 ME y de 872 MAP sobre su actividad asistencial mediante un cuestionario. Resultados: El 66% de los ME y el 30,5% de los MAP reconocen que el riesgo cardiovascular del paciente con DM2 es «muy alto». La mayoría considera unos objetivos concretos de concentración de colesterol asociado a las lipoproteínas de baja densidad (cLDL) basados en las guías europeas. Las estatinas más empleadas por ambos son la atorvastatina y la simvastatina, si bien ambos consideran que la estatina más adecuada sería la rosuvastatina. El 82 y el 68% de los ME y MAP, respectivamente, reconocen que consiguen los objetivos de cLDL en > 50% de sus pacientes, siendo la falta de adherencia y la presión de la administración las razones más importantes para no alcanzarlos. El 74% de los ME reconoce que no existen protocolos comunes con MAP. Conclusiones: La distinta percepción del riesgo real del paciente, el menor uso de estatinas consideradas más adecuadas, la falta de adherencia y la falta de la percepción en el control de cLDL pueden contribuir a que no se alcancen los objetivos terapéuticos de la dislipidemia aterogénica en pacientes con DM2
Introduction: Treatment of atherogenic dyslipidemia (AD) in type 2 diabetes (DM2) should focus on the global control of dyslipidemia. The aim of this study was to determine how hospital (MSs) and primary care specialist (GPs) from Spain manage AD in DM2 during their daily practice. Methods: An observational, cross-sectional, multicentric study was conducted. Information about daily practice was obtained from 497 MSs and 872 GPs across Spain. Results: 66% of MSs and 30.5% of GPs considered DM2 patients to be high-risk. Most consider the c-LDL targets based on European guidelines. The statins most widely used are atorvastatin and simvastatin. However both MSs and GPs considered rosuvastatin to be the most appropriate statin for these patients. 82% of MSs and 68% of GPs considered that > 50% of their patients achieved the c-LDL target. The main reasons of not achieving this target were lack of treatment adherence and pressure from the administration. Seventy four percent of MSs reported that there are no common clinical protocols with GPs. Conclusions: The differences in the perception of the real cardiovascular risk of the patient, low use of more appropriate statins, lack of adherence and poor perception of real c-LDL control may contribute to the failure in achieving lipid targets in DM2